Show simple item record

dc.contributor.authorGreally, Peter
dc.contributor.authorWhitaker, Paul
dc.contributor.authorPeckham, Daniel
dc.date.accessioned2012-12-07T11:43:59Z
dc.date.available2012-12-07T11:43:59Z
dc.date.issued2012-06
dc.identifier.citationChallenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. 2012, 28 (6):1059-67 Curr Med Res Opinen_GB
dc.identifier.issn1473-4877
dc.identifier.pmid22401602
dc.identifier.doi10.1185/03007995.2012.674500
dc.identifier.urihttp://hdl.handle.net/10147/254896
dc.description.abstractPseudomonas aeruginosa (Pa) is the predominant pathogen infecting the airways of patients with cystic fibrosis (CF). Initial colonization is usually transient and associated with non-mucoid strains, which can be eradicated if identified early. This strategy can prevent, or at least delay, chronic Pa infection, which eventually develops in the majority of patients by their late teens or early adulthood. This article discusses the management and latest treatment developments of Pa lung infection in patients with CF, with a focus on nebulized antibiotic therapy.
dc.language.isoenen
dc.publisherCurrent medical research and opinionen_GB
dc.rightsArchived with thanks to Current medical research and opinionen_GB
dc.subject.meshAdministration, Inhalation
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshChronic Disease
dc.subject.meshCystic Fibrosis
dc.subject.meshDrug Resistance, Bacterial
dc.subject.meshHumans
dc.subject.meshModels, Biological
dc.subject.meshPseudomonas Infections
dc.subject.meshPseudomonas aeruginosa
dc.subject.meshRespiratory Tract Infections
dc.titleChallenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.en_GB
dc.typeArticleen
dc.contributor.departmentNational Children's Hospital, Tallaght, Dublin, Ireland. Peter.Greally@amnch.ieen_GB
dc.identifier.journalCurrent medical research and opinionen_GB
dc.description.provinceLeinsteren
html.description.abstractPseudomonas aeruginosa (Pa) is the predominant pathogen infecting the airways of patients with cystic fibrosis (CF). Initial colonization is usually transient and associated with non-mucoid strains, which can be eradicated if identified early. This strategy can prevent, or at least delay, chronic Pa infection, which eventually develops in the majority of patients by their late teens or early adulthood. This article discusses the management and latest treatment developments of Pa lung infection in patients with CF, with a focus on nebulized antibiotic therapy.


This item appears in the following Collection(s)

Show simple item record